
FDA approves generic drug product for feline postoperative pain
Robenacoxib tablets from ZyVet Animal Health are bioequivalent to Onsior (Elanco Animal Health).
FDA officials have approved the first generic robenacoxib tablets for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration in cats. Sponsored by ZyVet Animal Health, the drug is indicated for felines 4 months and older, weighing at least 5.5 lb.1
Robenacoxib tablets are a nonsteroidal anti-inflammatory drug. These generic tablets are bioequivalent to Onsior, the brand-name drug product from Elanco Animal Health that was first approved by the FDA in 2011.1
RELATED:
An in vivo blood level study was conducted in 34 healthy, fasted cats to determine bioequivalence. Both the generic and brand-name products contained 6 mg of robenacoxib, the active ingredient, in each tablet, and no serious adverse effects were reported in the study.2
Robenacoxib tablets are available with a veterinarian’s prescription and can be administered orally once daily for up to 3 days. The approved dose of robenacoxib tablets is 0.45 mg/lb, according to the FDA.1,2
The generic robenacoxib product is flavored and supplied in blister cards containing 3 tablets. Each veterinary carton contains 10 blister cards. One card per patient should be dispensed with an envelope containing a veterinary insert and an owner information sheet.2
RELATED:
References
- FDA approves first generic robenacoxib tablet for postoperative pain & inflammation in cats. News release. FDA. January 9, 2026. Accessed January 9, 2026.
https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-robenacoxib-tablet-postoperative-pain-inflammation-cats?utm_medium=email&utm_source=govdelivery - Freedom of Information Summary. FDA. December 22, 2025. Accessed January 9, 2025.
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17827
Newsletter
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.




